top of page
Laxxon Medical to Present Innovative Oral GLP-1 Agonist including Multi-Compartment Micro-Tablet Form at 2024 BIO-Europe Convention, Aiming to Enhance Compliance for Special Patient Groups
Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID® at...
Laxxon Medical
Oct 14, 20243 min read
Laxxon Medical to Attend CPHI Milan 2024, Showcasing the cGMP Printing Technology at Adare Pharma Solution’s Facility in Pessano, Italy
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Laxxon Medical , a US-based pharma-technology company pioneering a new generation of...
Laxxon Medical
Oct 9, 20242 min read
Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US
The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP fa
Laxxon Medical
Oct 2, 20243 min read
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Learn more about Laxxon Medical's groundbreaking 3D printed oral GLP-1 asset, offering an alternative to injections in obesity treatments.
Laxxon Medical
May 22, 20242 min read
Investing in Safety: Laxxon Medical's QR Code Technology and the Fight Against Counterfeit Drugs
Counterfeit medicine is a threat to public health. Technologies like 3D printing and QR codes help protect both patients and drug integrity.
Laxxon Medical
May 20, 20246 min read
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Laxxon Medical announced its participation in the 2024 BIO International Convention, to showcase its LXM.2 asset to potential partners.
Laxxon Medical
May 16, 20242 min read
LXM.2 A 3D printed oral GLP-1 Agonist for weight loss
LXM.2 is Laxxon Medical’s oral GLP-1 Agonist treatment for weight loss, offering patients a non-invasive, once-a-day treatment made...
Laxxon Medical
May 13, 20243 min read
Understanding GLP-1 Medications for Diabetes and Obesity
Learn all about GLP-1 medications for diabetes and obesity, including benefits, side effects, and how they work.
Laxxon Medical
May 6, 20245 min read
The Controlled Release Drug Delivery Market
Explore the future of drug delivery, Laxxon Medical's innovative 3D technology, and how controlled-release drugs are reshaping healthcare.
Laxxon Medical
Apr 29, 20243 min read
Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024
Join Dr.Catherine Gatza, our VP of Regulatory Affairs, at the World Orphan Drug Congress USA 2024, in Boston, Massachusetts.
Laxxon Medical
Apr 23, 20242 min read
bottom of page